- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2049-3002
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Loss of hexokinase 1 sensitizes ovarian cancer to high-dose metformin ; volume:9 ; number:1 ; day:11 ; month:12 ; year:2021 ; pages:1-18 ; date:12.2021
Cancer & metabolism ; 9, Heft 1 (11.12.2021), 1-18, 12.2021
- Urheber
-
Šimčíková, Daniela
Gardáš, Dominik
Hložková, Kateřina
Hruda, Martin
Žáček, Petr
Rob, Lukáš
Heneberg, Petr
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40170-021-00277-2
- URN
-
urn:nbn:de:101:1-2022021819200143106066
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Šimčíková, Daniela
- Gardáš, Dominik
- Hložková, Kateřina
- Hruda, Martin
- Žáček, Petr
- Rob, Lukáš
- Heneberg, Petr
- SpringerLink (Online service)
Ähnliche Objekte (12)
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin
Author Correction: Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers
Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1
Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade
Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin
Author Correction: Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers
Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1
Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade
Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin
Author Correction: Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers
Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1
Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade